{
  "drug": "Kisqali (ribociclib)",
  "therapeutic_area": "Breast Cancer (HR+/HER2-)",
  "setting": "Secondary Care (Oncology)",
  "competitors": [
    "Ibrance (palbociclib)",
    "Verzenio (abemaciclib)"
  ],
  "priority_trusts": [
    {
      "name": "The Royal Marsden NHS Foundation Trust",
      "code": "RPY",
      "type": "Specialist Cancer Center",
      "reputation": "World-leading breast cancer research",
      "annual_patients": "High",
      "priority": "Critical"
    },
    {
      "name": "The Christie NHS Foundation Trust",
      "code": "RM2",
      "type": "Specialist Cancer Center",
      "reputation": "Largest single-site cancer center in Europe",
      "annual_patients": "Very High",
      "priority": "Critical"
    },
    {
      "name": "University College London Hospitals NHS Foundation Trust",
      "code": "RRV",
      "type": "Academic Medical Center",
      "reputation": "Leading research trials",
      "annual_patients": "High",
      "priority": "High"
    },
    {
      "name": "Guy's and St Thomas' NHS Foundation Trust",
      "code": "RJ1",
      "type": "Academic Medical Center",
      "reputation": "Major breast unit",
      "annual_patients": "High",
      "priority": "High"
    },
    {
      "name": "Cambridge University Hospitals NHS Foundation Trust",
      "code": "RGT",
      "type": "Academic Medical Center",
      "reputation": "Cambridge Breast Unit",
      "annual_patients": "Medium-High",
      "priority": "High"
    },
    {
      "name": "Imperial College Healthcare NHS Trust",
      "code": "RYJ",
      "type": "Academic Medical Center",
      "reputation": "Breast cancer research",
      "annual_patients": "High",
      "priority": "High"
    },
    {
      "name": "Manchester University NHS Foundation Trust",
      "code": "R0A",
      "type": "Academic Medical Center",
      "reputation": "The Christie collaboration",
      "annual_patients": "Very High",
      "priority": "Critical"
    },
    {
      "name": "Oxford University Hospitals NHS Foundation Trust",
      "code": "RTH",
      "type": "Academic Medical Center",
      "reputation": "Oxford Cancer Centre",
      "annual_patients": "Medium-High",
      "priority": "High"
    },
    {
      "name": "Royal Free London NHS Foundation Trust",
      "code": "RAL",
      "type": "Teaching Hospital",
      "reputation": "North London breast services",
      "annual_patients": "Medium",
      "priority": "Medium"
    },
    {
      "name": "King's College Hospital NHS Foundation Trust",
      "code": "RJZ",
      "type": "Academic Medical Center",
      "reputation": "Princess Royal Breast Unit",
      "annual_patients": "Medium-High",
      "priority": "High"
    }
  ],
  "nice_status": "Approved (TA495, TA563, TA612, TA725)",
  "key_differentiation": "Overall survival benefit (MONALEESA trials)",
  "strategic_focus": [
    "Specialist breast cancer centers",
    "KOL engagement",
    "Formulary parity with Ibrance",
    "OS data leverage"
  ],
  "immediate_actions": [
    "MSL engagement at Royal Marsden, Christie, UCLH",
    "KOL database build (30 targets)",
    "Formulary status audit (50 trusts)",
    "MONALEESA trial site mapping"
  ]
}